Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
More GEN Content From This Contributor
- Columns: Quo Vadis Biofuels Projects?
- Columns: Weeds and Reeds - The Invasion of the Second Generation Biofuel Crops
- Columns: International Students in the U.S. - A Diminishing Pool of Talent for Biotech?
- Columns: Thanks a lot, Bernie Madoff!
- Columns: Stimulate This!
- Columns: Biosimilar Approval in the U.S. and Europe: How Similar Are They?
- Columns: The New Face of Pharma R&D?
- Columns: Change Is the Air
- Columns: Pharma and Biotech Will Follow the Rest of the Economic Downward Trend – a Defensive Play no Longer
- Columns: Bias in Pharma Studies Published by the FDA—Shocking!!!
- Columns: Quotas for Women in Science
- Columns: The End of Nationalism (At Least in Pharma)
- Columns: The Japanese Acquisition Binge
- Columns: The Death of the Blockbuster
- Columns: Insourcing vs. outsourcing: the Roche-Genetech deal
- Columns: The Food Crisis - Exacerbated by Demand for Biofuel?
- Columns: The FDA Scale-Up: Good for Big Pharma or Not?
- Columns: Is Europe's Biotech Pipeline Empty?
- Columns: Awakening the Chinese (biotech) dragon
- Columns: No soup for you (no more) - VC-backed companies shooting for SBIR eligibility
- Columns: Big Pharma & Big Government = Big Profits?
- Columns: Post-doctoral paupers
- Columns: The Valley of Death